

EFPIA Disclosure Code - 2021 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Novartis Pharma AG works provide the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle, pharma companies work with scientists and healthcare professionals. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs and HCOs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, member companies made their best efforts to disclose relevant information for 2020.

Except in countries where disclosure is prescribed by laws, Novartis Pharma AG hereby confirms that its disclosures of transfers of value (ToVs) to HCPs and HCOs made in 2020 have been reported in application of the EFPIA Disclosure Code following key principles:

Disclosure quality

Novartis Pharma AG certifies that:

- Its disclosures are made in each country where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the codes and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Disclosure Code's requirements and applicable codes

Novartis Pharma AG certifies that:

- Data collection complies with the requirements of the EFPIA Disclosure Code;
- Actions were taken to ensure individual disclosure for HCPs' and HCOs' transfers of value (each as defined in the EFPIA Disclosure Code).

Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons.

Novartis Pharma AG certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Disclosure Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Ensuring compliance with Data Privacy Obligations

The collection, processing and disclosure of transfers of value have been made in accordance with the Data Privacy laws applicable in the respective countries.

Date: 11th June 2021

Name of signatory:
Susanne Schaffert

Position in the Company:
President Novartis Oncology

Signature